Entero Therapeutics (Nasdaq: ENTO)
Biotechnology Research
Overview
Overview
Industry
Founded Year
2014
Company Type
Public Company
Website
http://azurrx.com
Social Media
Specialty
Adrulipase, COVID-19 GI infections, Capeserod, Celiac, Celiac disease, Cystic Fibrosis, GI diseases, GI health, Gastrointestinal, Gastrointestinal diseases, Gastroparesis, Gluten, Gluten Intolerance, Gluten-free, Gluten-free diet, Latiglutenase, Lipase, Non-sytemic therapies, Pancreatitis, Recombinant proteins, Therapeutics, chronic pancreatitis, exocrine pancreatic insufficiency, immune checkpoint inhibitor colitis, niclosamide, pancreatic enzyme replacement therapy
Overview
Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: la read more company news read more company news read more company news read more company news...
FAQs
When was Entero Therapeutics (Nasdaq: ENTO) founded?
Entero Therapeutics (Nasdaq: ENTO) was founded in 2014.
What is Entero Therapeutics (Nasdaq: ENTO)'s official website?
Entero Therapeutics (Nasdaq: ENTO)'s official website is http://azurrx.com.
Find Contacts Everywhere
Find emails and phone numbers on LinkedIn, Company Websites and Your CRM!
